Benzinga | Mar 23, 2021 07:50AM EDT

Lantern Pharma To Present Data Supporting Advancement Of LP-184 At AACR Virtual Annual Meeting 2021 Apr. 20-15

Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR(r) artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, will present new data on LP-184, a next-generation, targeted small molecule in the acylfulvene drug class, showcasing its potency across various 2D and 3D models of prostate cancer, at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place from April 10-15, 2021.

Lantern's poster will highlight the spectrum of DNA damage repair defects, occurring in 25-30% of metastatic castration resistant prostate cancer (mCRPC) patients, against which LP-184 shows nanomolar potency. "In vitro studies of LP-184 continue to show potentially best in class efficacy in metastatic prostate cancer with a novel mechanism of action," stated Panna Sharma, CEO and President of Lantern Pharma. "Our ongoing work of LP-184 in metastatic prostate cancer in collaboration with Georgetown University has shown effectiveness in tumor models with mutations in DNA damage repair pathway components including in genes involved in Homologous Recombination and Transcription Coupled-Nucleotide Excision Repair. We look forward to sharing this new data at AACR and developing this compound towards the clinic and for the benefit of prostate cancer patients."

Details of the abstract are as follows:

Title: LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects

Session Category: Experimental and Molecular Therapeutics

Session Title: Novel Antitumor Agents

Permanent Abstract Number: 1249

The full text of the abstract is now available on the AACR Annual Meeting 2021 website.

The accompanying poster will be available to view to registered participants during the conference via the AACR e-poster website on April 10, 2021, and published on the company website after the conference.